Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07378072Recruiting
12-week daytime eating study for fatty liver in obesity
This study tests if restricting eating to daytime hours for 12 weeks can reduce liver fat in people with obesity. It aims to help those with fatty liver disease improve their health without medication.
AngersAges 18–65 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT07352228Enrolling by invitationPhase 4
Comparing carvedilol and propranolol to prevent variceal rebleeding
This trial tests whether carvedilol or propranolol works better to prevent another bleeding episode from enlarged veins in the stomach or esophagus (varices) after they have been treated with endoscopy. If you have cirrhosis and had a variceal bleed 6 to 30 days ago, this study may help find the most effective medicine for you.
Xi'anAges 18–75 - NCT05385237Recruiting
4D MRI scan to spot liver scarring
This study tests whether a special MRI scan (called 4D-MRI) can identify liver scarring or damage. It may help doctors measure liver fibrosis and inflammation without relying only on invasive tests.
Liestal, Basel-LandschaftAges 18 years+ - NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07201649Recruiting
Liver disease and artery calcification study
This study looks at how liver function and scarring affect calcium buildup in arteries. It may help people waiting for a liver transplant understand these changes.
Nice, Alpes-maritimesAges 18 years+ - NCT07185932RecruitingEarly Phase 1
Rifaximin for fatty liver with metabolic issues
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Birmingham, AlabamaAges 18 years+ - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT07046819RecruitingPhase 2
Tirzepatide for liver disease linked to alcohol use
This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.
Bethesda, MarylandAges 21–100 - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT06562803Recruiting
Cleaning the blood for liver failure with sepsis
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
Guangzhou, GuangdongAges 18–70 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT05178069RecruitingPhase 2
Probiotic supplement study for alcohol use disorder and liver injury
This Phase 2 trial studies whether a probiotic (LGG) can improve health in people with alcohol use disorder and alcohol-related liver injury. It’s not an alcohol treatment study, so participants are mainly joining to see how the supplement affects the body and liver-related outcomes.
Louisville, KentuckyAges 21–65 - NCT05433948Enrolling by invitation
Testing ways to diagnose mild brain changes in liver disease
This study looks at how well simple brain tests can detect early (minimal) thinking changes related to liver cirrhosis. It may help doctors spot these changes sooner and diagnose the condition more accurately.
EsbjergAges 18–90 - NCT05305287RecruitingPhase 4
Measuring liver energy use in people with diabetes and fatty liver disease
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
San Antonio, TexasAges 18–80 - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 196 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.